A detailed look at each stage of vaccine clinical testing
Each phase of clinical testing serves a specific purpose. Moving from one phase to the next requires meeting pre-defined criteria for safety and immune response. This staged approach protects participants while generating the evidence needed for regulatory approval.
This page provides a detailed breakdown of what happens at each phase, typical timelines, and what regulators look for before a vaccine can advance.
20-100 healthy adults (often younger, healthier population first)
Several months
Acceptable safety profile with no severe adverse events at the tested dose(s). Evidence that the vaccine induces an immune response. Dose(s) identified for advancement to Phase II.
Several hundred people, often including broader demographics (various ages, underlying conditions)
Months to 1-2 years
Consistent hundreds safety profile in of participants. Robust immune responses that meet pre-defined thresholds. Finalized formulation and dosing schedule selected for Phase III.
Thousands to tens of thousands; diverse populations across multiple geographic locations
1-4 years (or longer for some diseases)
Statistically significant efficacy (typically ≥50% reduction in disease compared to control). Acceptable safety profile with no major safety concerns. Enough data to satisfy regulatory agencies (FDA, EMA, etc.) for licensure.
Real Example: The Pfizer COVID-19 Phase III trial enrolled ~44,000 participants across multiple countries. The trial showed 95% efficacy against symptomatic COVID-19 and was the basis for emergency use authorization in December 2020.
Millions of people receiving the vaccine in routine use
Ongoing indefinitely
Phase IV uses systems like VAERS (Vaccine Adverse Event Reporting System) in the US, Yellow Card scheme in the UK, and VigiBase globally. These passive surveillance systems collect reports from healthcare providers and the public. Active surveillance (like V-safe in the US) directly polls vaccinated people for side effects.
Important: Phase IV can identify safety signals that weren't apparent in trials. When such signals emerge, regulatory agencies can update warnings, contraindicate for certain groups, or in rare cases, withdraw vaccine authorization.
• FDA. "Vaccine Development: 101." U.S. Food and Drug Administration.
• WHO. "Guidelines on Clinical Evaluation of Vaccines." World Health Organization, 2017.
• CDC. "COVID-19 Vaccine Safety Monitoring." Centers for Disease Control and Prevention.